Anavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer’s Disease

New Report Validates Therapeutic Application of Anavex Compounds in Tau Diseases NEW YORK, NY – May 21, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is encouraged by…

Anavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference

Company’s lead Sigma-1 agonist, ANAVEX 2-73 demonstrates robust anti-seizure effects in well established preclinical seizure models NEW YORK, NY – May 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types…

Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference

NEW YORK, NY – April 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a…

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries

Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases NEW YORK, NY – April 7, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time…

Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer’s Models at 2015 AD/PD™ Conference

ANAVEX 2-73 strong reversal of memory impairment in Alzheimer’s disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer’s disease models NEW YORK, NY – March 23, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s and other central nervous system…